Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 17 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Gloo Holdings, Inc. (NASDAQ: GLOO) Prices $72.8 Million IPO
Gloo (NASDAQ: GLOO) , a technology platform serving the faith and flourishing ecosystem, priced its…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Positioned for Growth as War Department Launches Billion-Dollar Push for U.S. Drone Dominance
Safe Pro Group (NASDAQ: SPAI), a mission-driven provider of AI-powered defense and security solutions, is…
-
QualityStocksNewsBreaks – Decent Holding Inc. (NASDAQ: DXST) Closes $8 Million Registered Offering of Class A Shares and Warrants
Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8…